203187-56-8

Basic information

• Product Name: ETHYL 3-HYDROXY-4-IODOBENZOATE
• Synonyms: ETHYL 3-HYDROXY-4-IODOBENZOATE;RARECHEM AL BI 0964;ETHYL 4-IODO 3-HYDROXY BENZOATE
• CAS NO: 203187-56-8
• Molecular Formula: C₉H₉IO₃
• Molecular Weight: 292.07
• Mol File: 203187-56-8.mol

Chemical Properties

• Melting Point: 119-120 °C
• Boiling Point: 313.606 °C at 760 mmHg
• Flash Point: 143.464 °C
• Appearance: /
• Density: 1.777 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.616
• PKA: 7.75±0.10(Predicted)
• CAS DataBase Reference: ETHYL 3-HYDROXY-4-IODOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-HYDROXY-4-IODOBENZOATE(203187-56-8)
• EPA Substance Registry System: ETHYL 3-HYDROXY-4-IODOBENZOATE(203187-56-8)

Safety Data

• Hazardous Substances Data: 203187-56-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
ETHYL 3-HYDROXY-4-IODOBENZOATE is used as a building block in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
ETHYL 3-HYDROXY-4-IODOBENZOATE is used in organic synthesis for the creation of a wide range of chemical products, including those with potential applications in various industries.
Used in Agrochemical Production:
ETHYL 3-HYDROXY-4-IODOBENZOATE is used as an intermediate in the production of agrochemicals, contributing to the development of products that can enhance agricultural productivity and crop protection.
It is important to handle ETHYL 3-HYDROXY-4-IODOBENZOATE with care and to follow proper safety procedures, as it can be hazardous if not handled properly.

InChI:InChI=1/C9H9IO3/c1-2-13-9(12)6-3-4-7(10)8(11)5-6/h3-5,11H,2H2,1H3

Upstream product

• 64-17-5 ethanol 
• 58123-77-6 3-hydroxy-4-iodobenzoic acid 
• 7781-98-8 ethyl-3-hydroxybenzoate 

Downstream Products

• 1425822-37-2 (S)-ethyl 4-[8-amino-1,2,4,5-tetrahydro-2-(2-methylpropyl)-4-(3-methylbutyl)-3-oxo-3H-1,4-benzodiazepin-7-yl]-3-[2-(benzyloxy)ethoxy]benzoate 
• 1425822-40-7 C₂₉H₄₁N₃O₅ 
• 1429230-67-0 C₂₄H₃₁BO₆ 
• 1425822-34-9 ethyl 3-[2-(benzyloxy)ethoxy]-4-iodobenzoate 
• 1459128-87-0 ethyl 3-(2-ethoxy-2-oxoethoxy)-4-iodobenzoate 
• 1258071-57-6 ethyl 2-phenylbenzofuran-6-carboxylate 
• 741699-04-7 3-ethoxy-4-iodo-benzoic acid ethyl ester 

Relevant articles and documents

MACROCYCLIC COMPOUND AND USE THEREOF

A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

Structure-activity relationship of benzodiazepine derivatives as LXXLL peptide mimetics that inhibit the interaction of vitamin D receptor with coactivators

Suppression of vitamin D receptor (VDR)-mediated transcription is expected to be of therapeutic value in Paget's disease of bone. It is known that interaction between VDR and coactivators is necessary for VDR transactivation, and the interaction occurs wh

AMPA RECEPTOR POTENTIATORS

The present invention relates to AMPA receptor potentiators of Formula I: formulations comprising them, methods for their use, and intermediates useful for their preparation.

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression. and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy. wherein Ar1 is substituted, by at least one R1 group selected from: -O(CRaRb)nC(O)NRXRy, -O(CH2)nCN, -O(CH2)nO(CH2)mOR2, -O(CH2)nCO2R2, -OS02NRxRy, -OSO2(CH2)pCH3, -(CRaRb)nC(O)NRXRy, -(CH2)nCN, -(CH2)nO(CH2)mOR2, -(CH2)nCO2R2, -(CH2)nC(O)R2, - SO2NRxRy, -SO2(CH2)pCH3, -CH=CHC(O)NRxRy, -CH=CHCN, -CH=CHCO2R2, -CO2R2, - C(O)R2, -C(O)NRxRy and C2-5alkenyl.